August 2026 in “LUMEN ET VIRTUS” In this study, low-dose oral minoxidil for androgenetic alopecia was generally safe, showing small average changes in blood pressure and heart rate with infrequent cardiovascular issues, though monitoring is essential, especially in patients with conditions like hypertension or arrhythmias.
June 2026 in “EP Europace” This study found that minoxidil and finasteride, commonly used for androgenetic alopecia, were associated with different arrhythmia profiles in adverse event reports: minoxidil predominantly with supraventricular arrhythmias and finasteride primarily with ventricular arrhythmias in men.
September 2025 in “Medicine” This study found that male patients with androgenetic alopecia exhibited signs of increased arrhythmia risk, such as higher P-wave dispersion and lower corrected QT interval on ECG, suggesting potential benefits from closer cardiac monitoring.
April 2025 in “Journal of Diabetes & Metabolic Disorders” This study found that linc-PINT expression was significantly decreased in patients with atrial fibrillation compared to healthy controls, while several TGF-β signaling genes were increased, suggesting a potential role in heart arrhythmias' pathogenesis.
December 2024 in “NeoReviews” This case study highlights that maternal autoimmune diseases like Sjogren syndrome may lead to congenital heart block in neonates, necessitating thorough evaluation of maternal medical history when such conditions present postnatally.